Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.

Dana E Rathkopf, Steven M Larson, Aseem Anand, Michael J Morris, Susan F Slovin, David R Shaffer, Glenn Heller, Brett Carver, Neal Rosen, Howard I Scher

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science